Clinical Trial Update: JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating JS107 versus investigator's choice as second-line or later therapy for CLDN18.2-positive advanced gastric or gastroesophageal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• JS107

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING